Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | RET C634R |
Gene Variant Detail | |
Relevant Treatment Approaches | RET Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634R RET V804G | Advanced Solid Tumor | sensitive | Vandetanib | Preclinical | Actionable | In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865). | 15184865 |
RET C634R RET V804M | Advanced Solid Tumor | resistant | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). | 19029224 |
RET C634R RET Y806C | Advanced Solid Tumor | resistant | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). | 19029224 |
RET C634R RET Y806E | Advanced Solid Tumor | resistant | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). | 19029224 |
RET C634R RET Y806F | Advanced Solid Tumor | predicted - sensitive | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224). | 19029224 |